NEW YORK (GenomeWeb) – Curetis reported today a 38 percent drop in revenues for the full-year 2016, reflecting the receipt of nonrecurring Unyvero molecular diagnostic system revenues the year before.

For the 12-month period ended Dec. 31, 2016, Curetis' revenues fell to €1.3 million ($1.4 million) from €2.1 million in 2015. The company noted that its 2015 revenues included €900,000 in nonrecurring Unyvero sales to Asian partners for clinical trials and regulatory clearances, as well as €300,000 in pharma revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.